Opinion
Video
Multiple Myeloma Frontline Horizon: Quads, Bispecifics, and Breakthroughs
Experts review groundbreaking insights from review the 2023 American Society of Hematology Annual Meeting and Exposition (ASH 2023) and discuss the paradigm shift in myeloma frontline treatments, exploring quads, bispecifics, and the dynamic evolution of therapeutic approaches.
This is a video synopsis/summary of a Peer Exchange featuring Joshua Richter, MD; Rafat Abonour, MD; Faith Davies, MD; and Amrita Krishnan, MD.
The panel discusses the future of multiple myeloma treatment, envisioning significant changes in the next 3 years. Krishnan emphasizes the importance of treatment discontinuation and the early use of bi-specifics, especially with upcoming trials such as CARTITUDE-6 (NCT05257083). Abonour reflects on the remarkable progress in myeloma treatment over the past 20 years and predicts a shift from proteasome inhibitors to bispecific T cell–directed therapy in upfront settings. Davies highlights the significance of deep responses, long progression-free survival, and the blurring line between transplant-eligible and noneligible patients. Richter anticipates the decline of quadruplet therapies and explores the potential of intentionally curing more patients through tailored approaches and treatment discontinuation.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
